Michelle Müller

Medicine · Health Sciences

8h-index343citations42works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Congenital Heart Disease Studies(6), Parkinson's Disease Mechanisms and Treatments(3), SARS-CoV-2 and COVID-19 Research(3), Aortic Disease and Treatment Approaches(3), Chronic Lymphocytic Leukemia Research(3)

Publications42 total

Validation of arginine-stimulated copeptin cut-offs for diagnosing AVP deficiency (central diabetes insipidus)
Endocrine Abstracts·2025
Abstract 3785: CFON-026 is a macrocycle that disrupts the BTK protein scaffold thereby inhibiting all clinically relevant BTK resistance mutations
Cancer Research·2025
Abstract 5468: A novel kinase degrader antibody conjugate for the treatment of mCRPC
Cancer Research·2025· 1 cited
151 (PB139): CFON-026, a best-in-class macrocyclic non-covalent inhibitor of BTK (WT) and all clinically relevant BTK resistance mutations
European Journal of Cancer·2024
183 (PB171): A novel kinase degrader-based payload for the development of potent Degrader Antibody Conjugates (DACs)
European Journal of Cancer·2024· 1 cited
From Benign Lipoma to G3 Liposarcoma: Contrast-Enhanced Ultrasound Reveals Tumor Microperfusion and Indicates Malignancy
Ultrasound in Medicine & Biology·2024Open Access
Predicting the optimal deep brain stimulation contact-level in Parkinson's disease: Insights from local field potentials recorded by the implanted neurostimulator
Parkinsonism & Related Disorders·2024Open Access
Abstract 6044: EPriL: A platform for the rapid identification of degraders of inhibitor-resistant kinases
Cancer Research·2024
Abstract 1960: CFON-026 is a potent non-covalent BTK inhibitor suitable for combination therapy with covalent BTK inhibitors for early eradication of resistance mutations
Cancer Research·2024· 1 cited
Abstract 5814: EPriL macrocycles as a platform for the rapid generation of effective kinase degrader antibody conjugates (DACs)
Cancer Research·2024
The mobile vaccine equity enhancement program–a model program for enhancing equity in vaccine availability based at a large health care system
Frontiers in Public Health·2023· 3 citedOpen Access
Ex vivo models for intestinal translocation studies of cellulose nanocrystals
In vitro models·2023· 3 citedOpen Access
Alveolar epithelial-like cell differentiation in a dynamic bioreactor: a promising 3D-approach for the high-throughput generation of lung cell types from human induced pluripotent stem cells
In vitro models·2023· 5 citedOpen Access
Wrap It! Preventive Antimicrobial Treatment Shows No Negative Effects on Tenocytes and Tendons—A Comprehensive Approach
Journal of Clinical Medicine·2023· 2 citedOpen Access
Development and Characterization of a 96‐Well Exposure System for Safety Assessment of Nanomaterials
Small·2023· 11 citedOpen Access
Advanced In Vitro Lung Models for Drug and Toxicity Screening: The Promising Role of Induced Pluripotent Stem Cells (Adv. Biology 2/2022)
Advanced Biology·2022Open Access
Neurological Outcome of Aortic Arch Reconstruction Using Selective Cerebral Perfusion Compared to Standard Open-Heart Surgery in Pediatric Patients: A Prospective Single-Center Study
The Thoracic and Cardiovascular Surgeon·2022
Advanced In Vitro Lung Models for Drug and Toxicity Screening: The Promising Role of Induced Pluripotent Stem Cells
Advanced Biology·2021· 38 citedOpen Access
Sea Bass Primary Cultures versus RTgill-W1 Cell Line: Influence of Cell Model on the Sensitivity to Nanoparticles
Nanomaterials·2021· 8 citedOpen Access
Abstract 1480: Comparative cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020
Cancer Research·2021
page 1 of 3Next →

Frequent Co-authors

Rogier C. Buijsman(11), Jan Gerard Sterrenburg(10), Joost C.M. Uitdehaag(10), Freek van Cauter(9), Martine B.W. Prinsen(9), Jos de Man(8), Winfried R. Mulder(8), Erik Ensing(7), Yvonne Kohl(6), K. Valeske(6), Hakan Akintürk(6), Joeri de Wit(5), Diep Vu(5), Yvonne Grobben(4), Nicole Willemsen‐Seegers(4), Guido J.R. Zaman(4), Dietmar Schranz(4), Diep Vu‐Pham(3), Antoon M. van Doornmalen(3), Sylvia Wagner(3)